1,680 Shares in Abbott Laboratories $ABT Acquired by Ewa LLC

Ewa LLC bought a new position in shares of Abbott Laboratories (NYSE:ABT) during the second quarter, according to its most recent Form 13F filing with the SEC. The fund bought 1,680 shares of the healthcare product maker’s stock, valued at approximately $229,000.

Other institutional investors have also made changes to their positions in the company. Hughes Financial Services LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $27,000. Abound Financial LLC acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $28,000. Elequin Capital LP acquired a new position in shares of Abbott Laboratories during the 1st quarter worth approximately $30,000. JCIC Asset Management Inc. acquired a new position in Abbott Laboratories in the 1st quarter valued at $32,000. Finally, Vision Financial Markets LLC acquired a new position in Abbott Laboratories in the 1st quarter valued at $33,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $133.53 on Thursday. The company has a quick ratio of 1.30, a current ratio of 1.82 and a debt-to-equity ratio of 0.25. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company has a market cap of $232.39 billion, a P/E ratio of 16.73, a P/E/G ratio of 2.54 and a beta of 0.69. The business has a fifty day simple moving average of $131.63 and a 200 day simple moving average of $131.24.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share for the quarter, hitting the consensus estimate of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same period in the prior year, the company earned $1.14 EPS. Abbott Laboratories’s revenue for the quarter was up 7.4% on a year-over-year basis. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. On average, sell-side analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th will be given a $0.59 dividend. The ex-dividend date is Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.8%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 29.57%.

Analyst Upgrades and Downgrades

ABT has been the topic of a number of research reports. Morgan Stanley upped their price objective on Abbott Laboratories from $127.00 to $137.00 and gave the company an “equal weight” rating in a report on Tuesday, July 15th. The Goldman Sachs Group upped their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a report on Wednesday. Jefferies Financial Group raised Abbott Laboratories from a “hold” rating to a “buy” rating and upped their price objective for the company from $143.00 to $145.00 in a report on Friday, July 18th. Leerink Partners initiated coverage on Abbott Laboratories in a report on Monday, June 16th. They issued a “market perform” rating and a $143.00 price objective on the stock. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $145.39.

Insider Buying and Selling

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of the stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the completion of the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.